Tiziana Life Sciences Falls on Withdrawn Public Offering

Dow Jones

2025/12/15

By Elias Schisgall

Tiziana Life Sciences shares fell after the biotechnology company said it was withdrawing a proposed public stock offering.

Shares were down 13% to $1.55 in Monday morning trading. The stock has more than doubled its value year-to-date.

The Boston-based company had filed a prospectus with the Securities and Exchange Commission Friday outlining preliminary steps for a public offering of shares. It said Monday morning it was withdrawing the proposal due to market conditions.

The Friday filing did not specify how many shares would be offered at what value. The company said it would have used proceeds from the filing to fund the development of intranasal foralumab, its leading drug candidate.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

December 15, 2025 10:33 ET (15:33 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2591640488"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591640488\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591640488?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591640488","market":"sg","top_or_hot":-1,"title":"Tiziana Life Sciences Falls on Withdrawn Public Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLSA\">Tiziana Life</a> Sciences shares fell after the biotechnology company said it was withdrawing a proposed public stock offering. \n</p>\n<p>\n  Shares were down 13% to $1.55 in Monday morning trading. The stock has more than doubled its value year-to-date. \n</p>\n<p>\n  The Boston-based company had filed a prospectus with the Securities and Exchange Commission Friday outlining preliminary steps for a public offering of shares. It said Monday morning it was withdrawing the proposal due to market conditions. \n</p>\n<p>\n  The Friday filing did not specify how many shares would be offered at what value. The company said it would have used proceeds from the filing to fund the development of intranasal foralumab, its leading drug candidate. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 10:33 ET (15:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tiziana Life Sciences Falls on Withdrawn Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTiziana Life Sciences Falls on Withdrawn Public Offering\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-12-15 23:33</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLSA\">Tiziana Life</a> Sciences shares fell after the biotechnology company said it was withdrawing a proposed public stock offering. \n</p>\n<p>\n  Shares were down 13% to $1.55 in Monday morning trading. The stock has more than doubled its value year-to-date. \n</p>\n<p>\n  The Boston-based company had filed a prospectus with the Securities and Exchange Commission Friday outlining preliminary steps for a public offering of shares. It said Monday morning it was withdrawing the proposal due to market conditions. \n</p>\n<p>\n  The Friday filing did not specify how many shares would be offered at what value. The company said it would have used proceeds from the filing to fund the development of intranasal foralumab, its leading drug candidate. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 10:33 ET (15:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLSA","symbol_name":"Tiziana Life Sciences PLC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591640488","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591640488","pubTimestamp":1765812780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tiziana Life Sciences shares fell after the biotechnology company said it was withdrawing a proposed public stock offering.Shares were down 13% to $1.55 in Monday morning trading. The stock has more than doubled its value year-to-date.The Boston-based company had filed a prospectus with the Securities and Exchange Commission Friday outlining preliminary steps for a public offering of shares. It said Monday morning it was withdrawing the proposal due to market conditions.The Friday filing did not specify how many shares would be offered at what value. The company said it would have used proceeds from the filing to fund the development of intranasal foralumab, its leading drug candidate.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLSA":"Tiziana Life Sciences PLC","BK4139":"生物科技"},"translate_title":"Tiziana Life Sciences因撤回公开募股而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLSA":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\nTiziana Life Sciences shares fell after the biotechnology company said it was withdrawing a proposed public stock offering. \n\n\n  Shares were down 13% to $1.55 in Monday morning trading. The stock has more than doubled its value year-to-date. \n\n\n  The Boston-based company had filed a prospectus with the Securities and Exchange Commission Friday outlining preliminary steps for a public offering of shares. It said Monday morning it was withdrawing the proposal due to market conditions. \n\n\n  The Friday filing did not specify how many shares would be offered at what value. The company said it would have used proceeds from the filing to fund the development of intranasal foralumab, its leading drug candidate. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 10:33 ET (15:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}